Total trials
103
Active
31
Phase 3
5
Total enrollment
16,809
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cisplatin | — | — | — | — | — | 1 | |
| Trastuzumab emtansine | — | — | — | — | — | 2 | |
| Paclitaxel | — | — | — | — | — | 2 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Oleclumab | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| MEDI4736 | — | — | — | — | — | 1 | |
| MEDI9447 | — | — | — | — | — | 1 | |
| Antibody-Drug Conjugates | — | — | — | — | — | 1 | |
| Ketorolac 10 Mg Oral | — | — | — | — | — | 1 | |
| Pregabalin 75mg | — | — | — | — | — | 1 | |
| Omeprazole 20mg | — | — | — | — | — | 1 | |
| Nivolumab 10 MG/ML Intravenous Solution | — | — | — | — | — | 1 | |
| Regorafenib 30 MG Oral | — | — | — | — | — | 1 | |
| Sustanon 250 | — | — | — | — | — | 1 | |
| Indocyanine Green | — | — | — | — | 7 | ||
| Adjuvant chemotherapy | — | — | — | — | — | 1 | |
| Total neoadjuvant therapy | — | — | — | — | — | 1 |
Next readouts
- 2025-03
- 2025-05-30
- 2026-01-01
- 2026-11
- 2026-12-31
- 2027-04-20
- 2027-11-01
- 2028-03
- 2029-12
- 2030-01
Top conditions
- Breast Cancer21
- Colorectal Cancer4
- Head and Neck Cancer3
- Peritoneal Carcinomatosis3
- Non Small Cell Lung Cancer3
- Hepatocellular Carcinoma2
- Cancer2
- Breast Neoplasms2
Frequently asked questions about Jules Bordet Institute
- How many clinical trials does Jules Bordet Institute have on ClinicalTrials.gov?
- Jules Bordet Institute is listed as the lead sponsor on 103 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Jules Bordet Institute's trials are in Phase 3?
- 5 of Jules Bordet Institute's trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does Jules Bordet Institute focus on?
- Jules Bordet Institute's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Peritoneal Carcinomatosis, Non Small Cell Lung Cancer.
- When are Jules Bordet Institute's next clinical trial readouts?
- Jules Bordet Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC”, expected around 2025-03.